Azanta is a privately-owned specialty pharma company founded in 1994 with a focus on medical treatments in women´s health, oncology and addiction medicine. Azanta seeks to be an international market leader within certain specialty pharma product categories, particularly in niche women's health and orphan oncology indications, employing innovative repositioning and drug formulation strategies. Azanta currently sells in-licensed and its own medical products in the Nordic countries and has pipeline of products in late stage development.
In April 2017, Azanta's new product Angusta® has been launched in the Nordics making Angusta® available for all women requiring induction of labour in these countries.
In addition, Azanta has a late stage product in clinical development: Nimoral, for the treatment of head and neck cancer patients undergoing radiotherapy. This products is currently being made available on compassionate use basis.
Azanta A/S employs a team of dedicated and proficient employees who, together with Azanta's partners and business collaborators, are keen to take Azanta A/S forward.
The company head office is located in Denmark. Azanta has affiliates in Norway, Sweden, Finland and the UK. Additionally, Azanta has agents in several countries serving the needs of Azanta and its customers locally.